H.C. Wainwright raised the firm’s price target on Benitec Biopharma (BNTC) to $35 from $28 and keeps a Buy rating on the shares. The company reported “highly positive” interim data reported from the first six patients to receive BB-301, the analyst tells investors in a research note. The firm says all six patients in the ongoing Phase 1b/2a trial met the formal statistical criteria for positive response in the proprietary oculopharyngeal muscular dystrophy responder analysis. H.C. Wainwright increased BB-301’s probability of approval to 45% from 40%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTC:
- Benitec Biopharma price target raised to $22 from $20 at Citizens JMP
- Benitec Biopharma’s BB-301 Receives FDA Fast Track
- Benitec provide interim clinical results for BB-301 Phase 1b/2a trial of BB-301
- Benitec Biopharma appoints Mates to board of directors
- Benitec Biopharma’s BB-301 Study: A Potential Game-Changer for OPMD Treatment?